The nonclassic secretion of thioredoxin is not sensitive to redox state

American Journal of Physiology - Cell Physiology

Volumn 284, Issue 5 53-5, 2003, Pages

  Tanudji, Marcel ^a   Hevi, Sarah ^a   Chuck, Steven L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Protein secretion; Protein trafficking

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; BREFELDIN A; MUTANT PROTEIN; THIOREDOXIN;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; CYTOSOL; DIMERIZATION; EXTRACELLULAR MATRIX; GOLGI COMPLEX; HUMAN; LOW TEMPERATURE; LYMPHOCYTE ACTIVATION; MUTATION; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TARGETING; SERUM;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS;

EID: 0037405868     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00521.2002     Document Type: Article

References (44)

1. Arner ES and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102-6109, 2000.
2. Baker A, Payne CM, Briehl MM, and Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 57: 5162-5167, 1997.
3. Balcewicz-Sablinska MK, Wollman EE, Gorti R, and Silberstein DS. Human eosinophil cytotoxicity-enhancing factor. II. Multiple forms synthesized by U937 cells and their relationship to thioredoxin/adult T cell leukemia-derived factor. J Immunol 147: 2170-2174, 1991.
4. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, and Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 16: 3459-3466, 1996.
5. Blobel G. Intracellular protein topogenesis. Proc Natl Acad Sci USA 77: 1496-1500, 1980.
6. Carreira CM, LaVallee TM, Tarantini F, Jackson A, Lathrop JT, Hampton B, Burgess WH, and Maciag T. S100A13 is involved in the regulation of fibroblast growth factor-1 and p40 synaptotagmin-1 release in vitro. J Biol Chem 273: 22224-22231, 1998.
7. Chang HC, Samaniego F, Nair BC, Buonaguro L, and Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11: 1421-1431, 1997.
8. Di Trapani G, Orosco C, Perkins A, and Clarke F. Isolation from human placental extracts of a preparation possessing 'early pregnancy factor' activity and identification of the polypeptide components. Hum Reprod 6: 450-457, 1991.
9. Di Trapani G, Perkins A, and Clarke F. Production and secretion of thioredoxin from transformed human trophoblast cells. Mol Hum Reprod 4: 369-375, 1998.
10. Evan GI, Lewis GK, and Bishop JM. Isolation of monoclonal antibodies specific for products of avian oncogene myb. Mol Cell Biol 4: 2843-2850, 1984.
11. +-ATPase. J Biol Chem 273: 544-551, 1998.
12. Florkiewicz RZ, Majack RA, Buechler RD, and Florkiewicz E. Quantitative export of FGF-2 occurs through an alternative, energy-dependent, non-ER/Golgi pathway. J Cell Physiol 162: 388-399, 1995.
13. Forman-Kay JD, Clore GM, Wingfield PT, and Gronenborn AM. High-resolution three-dimensional structure of reduced recombinant human thioredoxin in solution. Biochemistry 30:2685-2698, 1991.
14. Gallegos A, Gasdaska JR, Taylor CW, Painemurrieta GD, Goodman D, Gasdaska PY, Berggren M, Briehl MM, and Powis G. Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res 56: 5765-5770, 1996.
15. Gasdaska JR, Berggren M, and Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ 6: 1643-1650, 1995.
16. Hamon Y, Luciani MF, Becq F, Verrier B, Rubartelli A, and Chimini G. Interleukin-1β secretion is impaired by inhibitors of the ATP binding cassette transporter, ABC1. Blood 90: 2911-2915, 1997.
17. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, and Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-κB. J Biol Chem 274: 27891-27897, 1999.
18. Iwata S, Hori T, Sato N, Hirota K, Sasada T, Mitsui A, Hirakawa T, and Yodoi J. Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion: possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state. J Immunol 158: 3108-3117, 1997.
19. LaVallee TM, Tarantini F, Gamble S, Carreira CM, Jackson A, and Maciag T. Synaptotagmin-1 is required for fibroblast growth factor-1 release. J Biol Chem 273: 22217-22223, 1998.
20. Mehul B and Hughes RC. Plasma membrane targetting, vesicular budding and release of galectin 3 from the cytoplasm of mammalian cells during secretion. J Cell Sci 110: 1169-1178, 1997.
21. Melchior F and Gerace L. Mechanisms of nuclear protein import. Curr Opin Cell Biol 7: 310-318, 1995.
22. Menon RP and Hughes RC. Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem 264:569-576, 1999.
23. Mitsui A, Hirakawa T, and Yodoi J. Reactive oxygen-reducing and protein-refolding activities of adult T cell leukemia-derived factor/human thioredoxin. Biochem Biophys Res Commun 186: 1220-1226, 1992.
24. Nakamura H, De Rosa SC, Yodoi J, Holmgren A, Ghezzi P, and Herzenberg LA. Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc Natl Acad Sci USA 98: 2688-2693, 2001.
25. Nakamura H, Herzenberg LA, Bai J, Araya S, Kondo N, Nishinaka Y, and Yodoi J. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci USA 98: 15143-15148, 2001.
26. Pekkari K, Gurunath R, Arner ES, and Holmgren A. Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma. J Biol Chem 275: 37474-37480, 2000.
27. Powis G and Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 41: 261-295, 2001.
28. Rubartelli A, Bajetto A, Allavena G, Wollman E, and Sitia R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem 267: 24161-24164, 1992.
29. Rubartelli A, Cozzolino F, Talio M, and Sitia R. A novel secretory pathway for interleukin-1β, a protein lacking a signal sequence. EMBO J 9: 1503-1510, 1990.
30. Rubartelli A and Sitia R. Interleukin 1β and thioredoxin are secreted through a novel pathway of secretion. Biochem Soc Trans 19: 255-259, 1991.
31. Sahaf B, Soderberg A, Spyrou G, Barral AM, Pekkari K, Holmgren A, and Rosen A. Thioredoxin expression and localization in human cell lines: detection of full-length and truncated species. Exp Cell Res 236: 181-192, 1997.
32. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606, 1998.
33. Saraste J, Palade GE, and Farquhar MG. Temperature-sensitive steps in the transport of secretory proteins through the Golgi complex in exocrine pancreatic cells. Proc Natl Acad Sci USA 83: 6425-6429, 1986.
34. Silberstein DS, Dessein AJ, Elsas PP, Fontaine B, and David JR. Characterization of a factor from the U937 cell line that enhances the toxicity of human eosinophils to Schistosoma mansoni larvae. J Immunol 138: 3042-3050, 1987.
35. Silberstein DS, McDonough S, Minkoff MS, and Balcewicz-Sablinska MK. Human eosinophil cytotoxicity-enhancing factor eosinophil-stimulating and dithiol reductase activities of biosynthetic (recombinant) species with COOH-terminal deletions. J Biol Chem 268: 9138-9142, 1993.
36. Soderberg A, Sahaf B, and Rosen A. Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. Cancer Res 60: 2281-2289, 2000.
37. Tagaya Y, Maeda Y, Mitsui A, Kondo N, Matsui H, Hamuro J, Brown N, Arai K, Yokota T, Wakasugi H, and Yodoi J. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J 8: 757-764, 1989.
38. Tagaya Y, Okada M, Sugie K, Kasahara T, Kondo N, Hamuro J, Matsushima K, Dinarello CA, and Yodoi J. IL-2 receptor(p55)/Tac-inducing factor. Purification and characterization of adult T cell leukemia-derived factor. J Immunol 140: 2614-2620, 1988.
39. Tanudji M, Hevi S, and Chuck SL. Improperly folded green fluorescent protein is secreted via a non-classical pathway. J Cell Sci 115:3849-3857, 2002.
40. Wakasugi H, Wakasugi N, Tursz T, Tagaya Y, and Yodoi J. Production of an IL-1-like factor by 3B6 EBV-infected B cells [letter]. J Immunol 142: 2569-2570, 1989.
41. Wakasugi N, Tagaya Y, Wakasugi H, Mitsui A, Maeda M, Yodoi J, and Tursz T. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci USA 87: 8282-8286, 1990.
42. Weichsel A, Gasdaska JR, Powis G, and Montfort WR. Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. Structure 4: 735-751, 1996.
43. Williams CH, Arscott LD, Muller S, Lennon BW, Ludwig ML, Wang PF, Veine DM, Becker K, and Schirmer RH. Thioredoxin reductase two modes of catalysis have evolved. Eur J Biochem 267: 6110-6117, 2000.
44. Wollman EE, d'Auriol L, Rimsky L, Shaw A, Jacquot JP, Wingfield P, Graber P, Dessarps F, Robin P, Galibert F, Bertoglio J, and Fradelizi D. Cloning and expression of a cDNA for human thioredoxin. J Biol Chem 263: 15506-15512, 1988.